Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

1.89USD
22 Jun 2018
Change (% chg)

$-0.15 (-7.35%)
Prev Close
$2.04
Open
$2.19
Day's High
$2.19
Day's Low
$1.74
Volume
113,868
Avg. Vol
16,530
52-wk High
$12.10
52-wk Low
$1.65

Chart for

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for .

Overall

Beta: 2.49
Market Cap(Mil.): €18.78
Shares Outstanding(Mil.): 34.72
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 32.19 32.74
EPS (TTM): -7.51 -- --
ROI: -78.90 13.89 14.38
ROE: -286.17 16.72 16.08

BRIEF-Cytori Therapeutics Common Stock To Begin Trading On Adjusted Basis On May 24

* CYTORI THERAPEUTIC’S COMMON STOCK TO BEGIN TRADING ON ADJUSTED BASIS ON MAY 24, FOLLOWING ONE-FOR-TEN REVERSE SPLIT Source text for Eikon: Further company coverage:

May 23 2018

BRIEF-Cytori Reports Q1 2018 Business And Financial Results

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Cytori Provides Update On U.S. Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin

* CYTORI PROVIDES UPDATE ON U.S. MANUFACTURING AND EU APPROVAL PLANS FOR ATI-0918, LIPOSOMAL DOXORUBICIN

Apr 30 2018

BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO'S PLANS FOR HABEO CELL THERAPY - SEC FILING

Mar 16 2018

BRIEF-Cytori Q4 Adjusted Loss Per Share $0.10

* CYTORI REPORTS FOURTH QUARTER AND FULL YEAR 2017 BUSINESS AND FINANCIAL RESULTS

Mar 08 2018

BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board

* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD

Jan 29 2018

BRIEF-Swissquote Bank Sells 188,426 Shares Of Cytori Therapeutics Inc's Common Stock Between Jan 9-11

* SWISSQUOTE BANK SA REPORTS OPEN MARKET SALE OF 188,426 SHARES OF CYTORI THERAPEUTICS INC'S COMMON STOCK BETWEEN JAN 9 AND JAN 11 - SEC FILING Source text: (http://bit.ly/2ExdrAg) Further company coverage:

Jan 11 2018

BRIEF-Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017

* SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2CUutMr) Further company coverage:

Jan 08 2018

Earnings vs. Estimates